Advertisement

NON-STATIN THERAPY for LDL-Cholesterol Reduction in Primary and Secondary Prevention

Step 1
Register
Step 2
Pre-Test
Step 3
Video
Step 4
Post Test
Step 5
Evaluation
Step 6
Certificate
OBJECTIVES & ACCREDITATION

PROGRAM OVERVIEW
This program will focus on the evidence with, and use of, non-statin therapies for LDL-C lowering in the settings of primary and secondary prevention. An interpretation of recently presented and published secondary analyses from cardiovascular outcome trials with non-statin agents will provide lipid specialists with a more comprehensive evaluation of the efficacy and safety of non-statin therapy in patients with atherosclerotic cardiovascular disease (ASCVD). Users that view this activity will also receive an expert assessment of non-statin therapy for primary prevention. Four interactive challenging cases for lipid specialists with “real-world” patients will enable faculty members to describe best management strategies.

ACTIVITY TYPE
Release Date: July 2, 2018
Expiration Date: July 2, 2019
This activity is free of cost for participants.

TARGET AUDIENCE
This activity is designed to meet the needs of lipidologists, internists, endocrinologists, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management.

LEARNING OBJECTIVES
At the Conclusion of this activity, participants should be able to:

  • Explain the data from clinical studies with non-statin therapies for LDL-C lowering in primary and
  • secondary prevention patient populations.
  • Describe the roles for PCSK9 inhibitors and ezetimibe based on clinical trial evidence.
  • Identify multiple factors in selecting non-statin therapy for lowering LDL-C.
  • Recognize updated treatment recommendations for non-statin therapies in clinical practice guidelines.
  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

CRITERIA FOR SUCCESS
A statement of credit will be available upon completion of an online evaluation/claimed credit form. The deadline to claim credit is July 2, 2019. If you have any questions regarding the CME/CE credit, please contact cme@lipid.org.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

COMMERCIAL SUPPORT
This activity is supported by an educational grant from Amgen.

CREDIT DESIGNATION
CME credit provided by the National Lipid Association

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and VoxMedia. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this enduring internet activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.50 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

Pharmacist Accreditation Statement

Universal Activity Number – JA0007192-9999-18-020-H01-P (Knowledge)
This Activity has been approved for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
The maximum number of hours awarded for this CE activity is 1.8 contact hours.

For the advanced practice nurse, this activity has 1.2 contact hours of pharmacotherapy content.

CHAIR

James A. Underberg, MD, MS, FNLA
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY

FACULTY
Alan S. Brown, MD, FNLA
Director, Division of Cardiology
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL
Peter H. Jones, MD, FNLA
Director, Division of Cardiology
Associate Professor of Medicine Co-director,
Lipid Metabolism and Atherosclerosis Clinic Center for Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, TX
Pamela B. Morris, MD, FNLA
Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Charleston, SC

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

FACULTY/PLANNER FINANCIAL DISCLOSURES
Name Relationship Company
Brown, Alan Consultant Akcea Therapeutics, Amgen Inc., Kastle Therapeutics, KOWA Pharmaceuticals America, Inc., Regeneron Pharmaceuticals, Inc.
Honorarium Amgen Inc., KOWA Pharmaceuticals America, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis.
Jones, Peter Consultant Amgen Inc., Merck & Co., Inc., Regeneron and Sanofi
Morris, Pamela Consultant Amgen Inc., Esperion, Regeneron and Sanofi
Contracted Research Amgen Inc., Esperion
Underberg, James Advisory Board Akcea Therapeutics, Alexion, Amgen Inc., Invitae Corporation, Regeneron Pharmaceuticals, Inc., sanofi-aventis
Consultant Amarin Corporation, Amgen Inc.
Contracted Research Aegerion Pharmaceuticals
Speakers Bureau Alexion, Amarin Corporation, Amgen Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis, True Health Diagnostics
STAFF/ REVIEWER DISCLOSURES
NLA N/A NLA staff has nothing to disclose.
White, Thomas Speaker Amarin, Ionis, Janssen

0
No votes yet
Publish Date: 
Friday, June 22, 2018 - 16:30

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service